Passionate about IP! Since June 2003 the IPKat has covered copyright, patent, trade mark, designs, info-tech and confidentiality issues from a mainly UK and European perspective. Read, post comments and participate!

The team is Eleonora Rosati, Annsley Merelle Ward and Merpel. E-mail the Kats here!

The team is joined by GuestKats Söğüt Atilla, Oliver Fairhurst, Claire Gregg, Georgia Jenkins and Marcel Pemsel.

SpecialKats: Verónica Rodríguez Arguijo (TechieKat), Rose Hughes (PatKat) and Jocelyn Bosse (Book Review Editor).

InternKats: Wissam Bentazar, Simone Lorenzi and Kliment Markov.
Results for pharmaceutical IP

Monday Miscellany

While others are enjoying a restful long weekend, the IPKat has been hard at work identifying the latest events and opportunities that might...
- Monday, August 31, 2026
Monday Miscellany Monday Miscellany Reviewed by Jocelyn Bosse on Monday, August 31, 2026 Rating: 5
Commercial success is a nothing-burger for the EPO in Wegovy patent inventive step analysis (T 1701/22, Obesity treatment with semaglutide) Commercial success is a nothing-burger for the EPO in Wegovy patent inventive step analysis (T 1701/22, Obesity treatment with semaglutide) Reviewed by Dr Rose Hughes on Thursday, May 08, 2025 Rating: 5
Never Too Late: If you missed the IPKat last week! Never Too Late: If you missed the IPKat last week! Reviewed by Asude Sena Moya on Wednesday, February 26, 2025 Rating: 5
The benefits and pitfalls of drug manufacturing IP (T 2543/22) The benefits and pitfalls of drug manufacturing IP (T 2543/22) Reviewed by Dr Rose Hughes on Saturday, February 22, 2025 Rating: 5
The patent debate surrounding PrEP, the game-changer in HIV prevention The patent debate surrounding PrEP, the game-changer in HIV prevention Reviewed by Dr Rose Hughes on Monday, September 02, 2019 Rating: 5
Subscribe to: Posts ( Atom )
Powered by Blogger.